Scientists say heparin tainted deliberately

Scientists are increasingly suspicious that the heparin scandal is a case of Chinese fakery. The contaminant found in recalled heparin batches appears to be a chemically altered version of chondroitin sulfate, the joint-pain supplement, that was mixed into real heparin deliberately. "A child could tell you it's counterfeiting," one expert told the New York Times. "This is a deliberate act of chemically manipulating a heparin-like substance with heparin to increase the yield.

But investigators haven't fingerprinted the contaminant exactly, and they haven't proven that it caused the severe allergic reactions--including deaths--linked to the tainted heparin; indeed, some tainted batches apparently didn't set off the reactions. Nor do the experts know who added it to the real thing, or when, or where.

More than a dozen top scientists are working to unravel the mystery. And to keep the mystery contaminant out of the U.S. drug supply, the FDA asked manufacturers to run sophisticated tests  n their heparin products and ordered all untested heparin to be stopped at the border for analysis.

- read the story in the New York Times

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.